Mechanisms of Clinical Resistance to Selective FGFR2 Inhibition by Lirafugratinib [0.03%]
Lirafugratinib选择性FGFR2抑制的临床抗性机制
H Ellis,E R Balasooriya,A Varkaris et al.
H Ellis et al.
Background: Pan-FGFR inhibitors, targeting FGFR1-3 or FGFR1-4, are FDA-approved for FGFR2-driven cholangiocarcinoma. However, acquired resistance and dose-limiting toxicities from systemic FGFR inhibition constrain effica...
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial [0.03%]
一项针对既往接受过治疗的HER2阳性胃癌患者的随机III期临床试验(KC-WISE)中关于安贝那单抗的预设中期分析
R Liu,J Zhao,R Zhang et al.
R Liu et al.
Background: Gastric cancer after progression on trastuzumab treatment remains an unmet therapeutic challenge and is associated with suboptimal progression-free survival (PFS) and overall survival (OS). ...
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma [0.03%]
特瑞普利单抗联合化疗对比安慰剂联合化疗治疗晚期食管鳞状细胞癌患者的III期JUPITER-06研究的最终总生存分析及探索性生物标志物分析
Y X Chen,Y Jin,Y K Chen et al.
Y X Chen et al.
Background: The interim analysis of the JUPITER-06 study reveals significantly longer progression-free survival (PFS) and overall survival (OS) in advanced ESCC patients treated with toripalimab in combination with paclit...
European cancer mortality predictions for the year 2026: the levelling of female lung cancer mortality [0.03%]
欧洲癌症死亡率预测（2026年）：女性肺癌死亡率趋于稳定
C Santucci,S Mignozzi,F Levi et al.
C Santucci et al.
Background: We provided updated cancer mortality estimates for 2026 in the European Union (EU) and its five most populous countries, with a focus on lung cancer. ...
ctDNA-Guided Immunotherapy following Radical Cystectomy for Muscle-Invasive Bladder Cancer: Results from the TOMBOLA Trial [0.03%]
TOMBOLA试验：根治性膀胱切除术后的ctDNA指导免疫治疗结果
L Dyrskjøt,K Birkenkamp-Demtröder,I Nordentoft et al.
L Dyrskjøt et al.
Background: Standard treatment of localized muscle-invasive bladder cancer (MIBC) is neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC), but ∼50% of patients relapse within 2 years. Adjuvant immunotherapy...
Comment to: ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC) [0.03%]
ALBAN（GETUG-AFU 37）评论：Atezolizumab静脉给药联合卡介苗（BCG）膀胱内灌注对比单用BCG治疗高危、非肌层浸润性膀胱癌（NMIBC）患者的III期、开放标签、国际多中心随机临床试验
Roberto Contieri,Veronica Mollica,Shahrokh F Shariat et al.
Roberto Contieri et al.
From Algorithms to Meaningful Biomarkers: Anchoring AI in Clinical Oncology [0.03%]
从算法到有意义的生物标志物：在临床肿瘤学中锚定人工智能技术
E G E de Vries,E Garralda,S Litière
E G E de Vries
Machine learning reveals country-specific drivers of global cancer outcomes [0.03%]
机器学习揭示国家特定驱动因素对全球癌症预后的影响
M S Patel,C S Pramesh,N N Sanford et al.
M S Patel et al.
Background: Global inequities in access to cancer diagnostics and treatment contribute to wide variation in cancer mortality-to-incidence ratios (MIRs), a proxy for survival. We aimed to develop an interpretable machine l...
Erratum to 'Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis': [Annals of Oncology. Volume 36, Issue 11, November 2025, Pages 1389-1399] [0.03%]
关于“针对因1级间质性肺疾病/肺炎恢复后的特善赞德鲁克斯重新治疗的合并分析”的勘误：《肿瘤学年鉴》第36卷，第11期，2025年11月，第1389-1399页
H S Rugo,E Tokunaga,H Iwata et al.
H S Rugo et al.